Merck & Company, Inc. (NYSE:MRK) had its price target increased by stock analysts at Leerink Swann from $69.00 to $70.00 in a note issued to investors on Monday. The brokerage presently has a “market perform” rating on the stock. Leerink Swann’s price target would suggest a potential upside of 9.58% from the company’s previous close.

Several other equities analysts also recently issued reports on the stock. Jefferies Group LLC restated a “sell” rating and issued a $52.00 price objective on shares of Merck & in a research note on Sunday, August 20th. BMO Capital Markets restated a “buy” rating and issued a $72.00 price objective on shares of Merck & in a research note on Friday, September 8th. Credit Suisse Group decreased their price objective on shares of Merck & from $75.00 to $74.00 and set an “outperform” rating for the company in a research note on Wednesday, August 30th. BidaskClub downgraded shares of Merck & from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Finally, Cowen and Company restated a “hold” rating and issued a $70.00 price objective on shares of Merck & in a research note on Friday, September 1st. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $70.67.

Shares of Merck & (NYSE:MRK) traded down 0.34% during mid-day trading on Monday, reaching $63.66. The company’s stock had a trading volume of 6,825,463 shares. The stock has a 50 day moving average of $64.57 and a 200-day moving average of $63.70. The stock has a market cap of $173.62 billion, a P/E ratio of 34.47 and a beta of 0.80. Merck & has a one year low of $58.29 and a one year high of $66.80.

Merck & (NYSE:MRK) last released its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $0.14. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The company had revenue of $9.93 billion during the quarter, compared to the consensus estimate of $9.75 billion. During the same quarter in the prior year, the firm posted $0.93 earnings per share. Merck &’s revenue for the quarter was up .9% on a year-over-year basis. On average, equities research analysts expect that Merck & will post $3.87 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Merck & Company, Inc. (MRK) PT Raised to $70.00 at Leerink Swann” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/23/merck-company-inc-mrk-pt-raised-to-70-00-at-leerink-swann.html.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Perennial Advisors LLC raised its holdings in Merck & by 10.7% during the second quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock worth $104,000 after purchasing an additional 157 shares in the last quarter. Stelac Advisory Services LLC purchased a new position in Merck & during the second quarter worth about $104,000. Vigilant Capital Management LLC raised its holdings in Merck & by 16.7% during the first quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock worth $111,000 after purchasing an additional 250 shares in the last quarter. Cascade Investment Advisors Inc. raised its holdings in Merck & by 15.5% during the second quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock worth $111,000 after purchasing an additional 232 shares in the last quarter. Finally, Solaris Asset Management LLC raised its holdings in Merck & by 6.3% during the second quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock worth $124,000 after purchasing an additional 115 shares in the last quarter. 72.86% of the stock is owned by hedge funds and other institutional investors.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.